Cabazitaxel can offer an advantage in certain patients
Cabazitaxel (trade name: Jevtana) has been approved since March 2011 in men with metastatic prostate cancer who no longer respond to conventional therapy with hormone blockers and have already been pre-treated with the cytostatic drug docetaxel. In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether cabazitaxel offers an added benefit compared with the present standard therapy.
In patients aged 65 years or older and for whom further treatment with docetaxel is no longer an option, IQWiG found an indication of a considerable added benefit of cabazitaxel due to better survival prospects. In patients younger than 65 years, the data provide a "hint" of an added benefit; however, its extent cannot be precisely classified. An added benefit is not proven in patients who can still be treated with docetaxel, as adequate data are lacking.
Separate assessment for two groups of patients
In accordance with the specifications of the Federal Joint Committee (G-BA), IQWiG separately assessed the drug in two groups of patients. The G-BA has specified different appropriate comparator therapies for the two groups.
The "best supportive care population" contains patients for whom further treatment with docetaxel is no longer an option. The appropriate comparator therapy for this group is palliative treatment with dexamethasone, prednisone, prednisolone or methylprednisolone, as well as "best supportive care".
"Best supportive care" means the therapy that provides the patient with the best possible individually optimized supportive treatment to alleviate symptoms (e.g. suitable pain therapy) and improve quality of life.
The "docetaxel-retherapy population" comprises patients for whom docetaxel is still an option. The appropriate comparator therapy for this patient population is docetaxel in combination with prednisone or prednisolone.
Cabazitaxel can improve survival prospects
One study (TROPIC), which considered patient-relevant outcomes and provided relevant data, was included in the assessment of added benefit in the "best supportive care population". This study compared treatment with cabazitaxel versus mitoxantrone, in each case combined with prednisone and "best supportive care". In this context, mitoxantrone was regarded as a component of "best supportive care" for the assessment.
As IQWiG found, cabazitaxel can increase survival time, but the results vary with the age of patients. In patients aged 65 years or older, an indication of a major added benefit can be inferred with regard to overall survival. One can also assume an increase in survival time due to treatment with cabazitaxel in under 65-year-olds; however, the extent of this increase cannot be clearly determined, as the evidence base is less reliable here. In this age group, the data therefore only provide a "hint" of an added benefit, for which the extent cannot be quantified. The study also investigated the pain-relieving effect of the interventions as an aspect of the consequences of disease (morbidity). However, no relevant difference between the two treatment groups was shown. No data were available on health-related quality of life.
Also indication of greater harm due to severe side effects
In the "best supportive care population", the data also provide indications of greater harm in the form of side effects (adverse events). For example, severe adverse events, such as severe diarrhoea, anaemia or neutropenia, occurred more often in the cabazitaxel group. IQWiG classifies the extent of this greater harm as considerable for these outcomes. There is even an indication of major harm for the category "serious adverse events"; these are adverse events that, for example, lead to hospital admission, are life-threatening or fatal.
In the overall consideration of greater benefit (increase in survival time) and greater harm, IQWiG concludes that the data provide an indication of a considerable added benefit in patients aged 65 years or older. In under 65-year-olds, the data provide a "hint" of an unquantifiable, and, at most, considerable added benefit.
Added benefit in the docetaxel-retherapy population not proven
The drug manufacturer did not present data for the "docetaxel-retherapy population" in the dossier, and explained why docetaxel was not regarded as an appropriate comparator therapy. However, IQWIG does not follow this line of argument. An added benefit in the second patient group specified by the G-BA is therefore not proven.
G-BA decides on the extent of added benefit
The procedure for inferring the overall conclusion on the extent of added benefit is a proposal from IQWiG. The G-BA, which has opened a formal commenting procedure, decides on the extent of added benefit.
More information: www.gesundheitsinformation.de/
Provided by Institute for Quality and Efficiency in Health Care
- Abiraterone: Indication of considerable added benefit in certain patients Jan 06, 2012 | not rated yet | 0
- Pirfenidone: Extent of added benefit assessed Jan 03, 2012 | not rated yet | 0
- Added benefit of linagliptin is not proven Jan 06, 2012 | not rated yet | 0
- Boceprevir: Indication of added benefit for specific patients Dec 09, 2011 | not rated yet | 0
- Ticagrelor: Considerable added benefit for specific patients Oct 11, 2011 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
How can there be a term called "intestinal metaplasia" of stomach
20 hours ago Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013 As an experiment, for the past few months I've been consuming at least one portion of Jell-O or unflavored Knox gelatin per day. I'm 64, in very...
Alcohol and acetaminophen
May 13, 2013 Edit: sorry for the typo in the title , can't edit I looked around on google quite a bit and it's very hard to find precise information on the...
- More from Physics Forums - Medical Sciences
More news stories
The gap between life expectancy in patients with a mental illness and the general population has widened since 1985 and efforts to reduce this gap should focus on improving physical health, suggest researchers in a paper ...
Cancer 8 hours ago | not rated yet | 0
By studying the roles two proteins, thrombospondin-1 and prosaposin, play in discouraging cancer metastasis, a trans-Atlantic research team has identified a five-amino acid fragment of prosaposin that significantly reduces ...
Cancer 9 hours ago | not rated yet | 0
A novel transcriptome-based classification of colon cancer that improves the current disease stratification based on clinicopathological variables and common DNA markers is presented in a study published in PLOS Medicine this w ...
Cancer 9 hours ago | not rated yet | 0
A study of veterans at high risk for developing lung cancer shows that low-dose computed tomography (LDCT) can be highly effective in helping clinicians spot tiny lung nodules which, in a small number of patients, may indicate ...
Cancer 11 hours ago | not rated yet | 0
An attack on glioblastoma brain tumor cells that uses a modified poliovirus is showing encouraging results in an early study to establish the proper dose level, researchers at Duke Cancer Institute report.
Cancer 13 hours ago | not rated yet | 0
(Medical Xpress)—Native peoples in regions where cameras are uncommon sometimes react with caution when their picture is taken. The fear that something must have been stolen from them to create the photo ...
15 hours ago | 4.2 / 5 (5) | 0 |
(Medical Xpress)—Despite spending billions of dollars on research and development, drug companies have been unable to come up with effective treatments for dementia and Alzheimer's Disease (AD). Now, A. ...
13 hours ago | 4.9 / 5 (11) | 0 |
Australian scientists have charted the path of insulin action in cells in precise detail like never before. This provides a comprehensive blueprint for understanding what goes wrong in diabetes.
15 hours ago | 4.6 / 5 (7) | 0 |
An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.
8 hours ago | 3 / 5 (2) | 0
Activating an enzyme known to play a role in the anti-aging benefits of calorie restriction delays the loss of brain cells and preserves cognitive function in mice, according to a study published in the May ...
9 hours ago | 5 / 5 (4) | 0 |
10 hours ago | 5 / 5 (1) | 0 |